tbuckley/cabot-search huggingface dataset:
Microrna-9 and -224 In Trastuzumab Resistant HER2 Positive Breast Cancer Cells
Authors: K. Howe, A. Eustace, S. Souahli, B.C. Browne, S. Aherne, N. Barron, N. Walsh, J.P. Crown, N. O'Donovan
Journal: Annals of Oncology (2012)
Comparison of the Quality of Hospitals That Admit Medicare Advantage Patients vs Traditional Medicare Patients
Authors: David J. Meyers, Amal N. Trivedi, Vincent Mor, Momotazur Rahman
Journal: JAMA Network Open (2020)

<h3>Importance</h3> In the Medicare Advantage (MA) program, Medicare enrollees may be steered by their health plan to specific hospitals. Little is known about the quality of hospitals that serve MA enrollees. <h3>Objective</h3> To compare the quality of hospitals that admit MA enrollees with the quality of those that admit traditional Medicare enrollees. <h3>Design, Setting, and Participants</h3> This cross-sectional study used data from the 2012 to 2016 Medicare Provider Analysis and Review to compare quality of care, as measured by the star rating given by the Centers for Medicare and Medicaid Services and readmission rates, in hospitals that serve MA enrollees and traditional Medicare enrollees using multinomial logit models. Participants were 7 130 610 Medicare beneficiaries admitted to 2994 acute care hospitals across the United States in 2016. Data were analyzed between August 2018 and August 2019. <h3>Exposures</h3> The exposure was MA enrollment. Adjusters included demographic and clinical characteristics and zip code fixed effects. <h3>Main Outcomes and Measures</h3> Hospital Compare star ratings and quintiles of performance in 30-day readmission rates. <h3>Results</h3> The sample included 7 130 610 Medicare beneficiaries in 2016 (54.3% female; mean [SD] age, 72.7 [13.2] years). Of 12 190 270 total hospitalizations, 1 211 293 traditional Medicare and 494 352 MA patients were admitted to 718 low-readmission hospitals and 1 205 586 traditional Medicare and 526 955 MA patients were admitted to 597 high-readmission hospitals. Accounting for observed patient characteristics, MA enrollees less often entered either low- or high-quality hospitals and were more often admitted to average-quality hospitals. For nonemergent hospitalizations, MA enrollees were 1.9 percentage points (95% CI, 1.5-2.2 percentage points) less likely to enter a low-readmissions hospital, 5.1 percentage points (95% CI, 4.6-5.6 percentage points) more likely to enter an average-readmissions hospital, and 3.2 percentage points (95% CI, 2.9-3.5 percentage points) less likely to enter a high-readmissions hospital compared with traditional Medicare enrollees. Patients with MA were also 2.6 percentage points (95% CI, 2.2-2.9 percentage points) less likely to enter a 1- to 2-star hospital, 5.5 percentage points (95% CI, 4.9-5.9 percentage points) more likely to enter a 3-star hospital, and 2.8 percentage points (95% CI, 2.5-3.2 percentage points) less likely to enter a 4- to 5-star hospital compared with traditional Medicare enrollees. The differences were less pronounced for emergency admissions. <h3>Conclusions and Relevance</h3> This study found that enrollees in MA plans were more likely to be admitted to average-quality hospitals instead of either high- or low-quality hospitals, suggesting that MA plans may be steering their enrollees to specific hospitals.
Front-Line Treatment with Docetaxel, Cisplatin and Bevacizumab for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group (HORG)
Authors: N. Kentepozidis, M. Agelidou, C. Christophylakis, A. Kotsakis, N. Vardakis, D. Stoltidis, E. Kontopodis, A. Xyrafas, S. Agelaki, V. Georgoulias
Journal: Annals of Oncology (2012)
Association Between Peripheral Blood Lymphocyte Count (PBLC) and Outcome in Patients with Solid Tumors Treated with Ngr-Htnf
Authors: A. Bulotta, V. Gregorc, G. Rossoni, G. Todisco, M.G. Viganò, A. Lambiase, C. Bordignon
Journal: Annals of Oncology (2012)
Reporting of the Medical Licensing Examination—Reply
Authors: Jennifer L. Swails, Omowunmi Aibana, Barbara J. Stoll
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Predictive Markers for Overall and Progression-Free Survival with Capox in Second-Line Chemotherapy of Metastatic Colorectal Cancer
Authors: M.D.P. Solís Hernández, P. Jimenez Fonseca, Q. Perez, C. Alvarez Fernandez, L. Ruiz, D. Rodríguez Rubí, W. Li, M.L. Sánchez, L. Faez, J.M. Viéitez
Journal: Annals of Oncology (2012)
IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution
Authors: Mariette Odabashian, Emanuela Carlotti, Shamzah Araf, Jessica Okosun, Filomena Spada, John G. Gribben, Francesco Forconi, Freda K. Stevenson, Mariarita Calaminici, Sergey Krysov
Journal: Blood (2020)
Association of State Laws Regarding Snacks in US Schools With Students' Consumption of Solid Fats and Added Sugars
Authors: Lindsey Turner, Julien Leider, Elizabeth Piekarz-Porter, Jamie F. Chriqui
Journal: JAMA Network Open (2020)

<h3>Importance</h3> The Smart Snacks in School standards (hereafter,<i>Smart Snacks</i>) were issued in 2013 with the aim of improving students' dietary intake behaviors. Goals of Smart Snacks included reducing total energy intake, consumption of solid fats and added sugars, and sodium intake. Smart Snacks standards were required to be implemented by the start of the 2014 to 2015 school year at all US schools participating in federal child nutrition programs. <h3>Objective</h3> To examine the association of state laws that specifically direct schools to implement Smart Snacks with student dietary consumption outcomes. <h3>Design, Setting, and Participants</h3> This cross-sectional study used nationally representative data collected in the 2014 to 2015 school year as part of the School Nutrition and Meal Cost Study. Students in grades 1 through 12 (ages approximately 6-18 years) were randomly selected from 310 public schools in 30 US states and the District of Columbia. Analytic weights were applied and all percentages reported are weighted. Analyses were conducted from March 1, 2018, to December 12, 2019. <h3>Exposures</h3> State laws requiring schools to implement Smart Snacks. <h3>Main Outcomes and Measures</h3> A 24-hour recall was used to assess student dietary intake as daily kilocalories consumed as (a) total energy, (b) solid fats and added sugars combined, (c) solid fats, or (d) added sugars. Milligrams of daily sodium consumption were also computed. <h3>Results</h3> Among 1959 students (mean [SD] age, 11.9 [3.5] years; 1014 [50.9%] boys), 420 students (22.5%) attended school in a state with Smart Snacks laws, and 528 students (26.1%) consumed snacks obtained at school. In covariate-adjusted models, total energy intake did not vary based on state law. Adjusted mean daily kilocalories from solid fats and added sugars was significantly lower among students in states with laws (508.7 [95% CI, 463.0 to 554.4] kcal) than among students in states without laws (562.5 [95% CI, 534.3 to 590.8] kcal; difference, −53.9 [95% CI, −104.5 to −3.2] kcal;<i>P</i> = .04). Consumption of sodium did not differ by state law. Kilocalories from solid fats contributed more to the difference than kilocalories from added sugars (−37.7 [95% CI −62.8 to −12.6] kcal vs −16.2 [95% CI, −51.3 to 19.0] kcal). <h3>Conclusions and Relevance</h3> These findings suggest that students in states with laws requiring schools to implement Smart Snacks had better dietary intake than students in states without laws, consuming a mean of 53.9 fewer kilocalories from solid fats and added sugars per day, after adjusting for covariates. State-level policy mechanisms may support schools' implementation of federal standards in ways that are associated with healthier diets among children and adolescents.
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults
Authors: Stuart H. Isaacson, William Ondo, Carlayne E. Jackson, Richard M. Trosch, Eric Molho, Fernando Pagan, Mark Lew, Khashayar Dashtipour, Thomas Clinch, Alberto J. Espay
Journal: JAMA Neurology (2020)

RimabotulinumtoxinB (RIMA) may be preferable as an anti-sialorrhea treatment compared with current oral anticholinergic drugs in people with neurological disorders.To assess the safety, efficacy, and tolerability of RIMA injections for the treatment of sialorrhea in adults.This randomized, parallel, double-blind, placebo-controlled clinical trial of RIMA 2500 U and 3500 U was conducted from November 14, 2013, to January 23, 2017. A total of 249 adult patients with troublesome sialorrhea secondary to any disorder or cause were screened. Of them, 13 refused further participation in the study or were lost to follow-up and 49 did not fulfill the criteria for participation; 187 were ultimately enrolled. Patients had to have a minimum unstimulated salivary flow rate (USFR) of 0.2 g/min and a minimum Drooling Frequency and Severity Scale score of 4.Patients were randomized 1:1:1 to RIMA, 2500 U (n = 63); RIMA, 3500 U (n = 64); or placebo (n = 60).Primary outcomes were the change in USFR from baseline to week 4 and the Clinical Global Impression of Change (CGI-C) at week 4. The CGI-C scores were recorded on a 7-point scale ranging from very much improved to very much worse. Adverse events were recorded throughout the trial period.Of 187 patients enrolled (147 men [78.6%]; mean [SD] age, 63.9 [13.3] years), 122 patients had Parkinson disease (65.2%), 13 (7.0%) were stroke survivors, 12 had amyotrophic lateral sclerosis (6.4%), 6 had medication-induced sialorrhea (3.2%), 4 had adult cerebral palsy (2.1%), and 30 had sialorrhea owing to other causes (16.0%). A total of 176 completed the study. Treatment with both doses of RIMA significantly reduced USFR at week 4 vs placebo (mean treatment difference, -0.30 g/min [95% CI, -0.39 to -0.21] for both doses vs placebo, P < .001). The CGI-C scores were statistically significantly improved at week 4 for both treatment groups vs placebo (-1.21 [95% CI, -1.56 to -0.87] for 2500 U, -1.14 [95% CI, -1.49 to -0.80] for 3500 U, both P < .001). Treatment benefits were seen as early as 1 week after injection and were maintained over the treatment cycle of approximately 13 weeks. The RIMA injections were well tolerated compared with placebo. The most common adverse events were self-limited mild to moderate dry mouth, dysphagia, and dental caries.Treatment with RIMA (2500 U and 3500 U) in adults was well tolerated and reduced sialorrhea, with the onset of the effect at 1 week after the injection. These data support the clinical use of RIMA in the management of sialorrhea in adults.ClinicalTrials.gov Identifier: NCT01994109.
Announcing the 100th Anniversary of <i>JAMA Surgery</i>, 1920 to 2020
Authors: Melina R. Kibbe, Howard Bauchner
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona
Authors: Zhenbao Li, Yongqi Wang, Jiaojiao Zhu, Yachao Zhang, Wenjing Zhang, Mei Zhou, Cong Luo, Zegeng Li, Biao Cai, Shuangying Gui, Zhonggui He, Jin Sun
Journal: Journal of Controlled Release (2020)
Ocular Adverse Effects (OAES) of Molecularly Targeted Agents (MTAS) Approved in Oncology: A Systematic Review
Authors: O. Huillard, S. Bakalian, C. Levy, L. Desjardins, L. Lumbroso, S. Pop, M. Sablin, V. Diéras, C. Le Tourneau
Journal: Annals of Oncology (2012)
Post-discharge acute care and outcomes following readmission reduction initiatives: national retrospective cohort study of Medicare beneficiaries in the United States
Authors: Rohan Khera, Yongfei Wang, Susannah M Bernheim, Zhenqiu Lin, Harlan M Krumholz
Journal: BMJ (2020)

Abstract Objectives To determine whether patients discharged after hospital admissions for conditions covered by national readmission programs who received care in emergency departments or observation units but were not readmitted within 30 days had an increased risk of death and to evaluate temporal trends in post-discharge acute care utilization in inpatient units, emergency departments, and observation units for these patients. Design Retrospective cohort study. Setting Medicare claims data for 2008-16 in the United States. Participants Patients aged 65 or older admitted to hospital with heart failure, acute myocardial infarction, or pneumonia—conditions included in the US Hospital Readmissions Reduction Program. Main outcome measures Post-discharge 30 day mortality according to patients’ 30 day acute care utilization; acute care utilization in inpatient and observation units and the emergency department during the 30 day and 31-90 day post-discharge period. Results 3 772 924 hospital admissions for heart failure, 1 570 113 for acute myocardial infarction, and 3 131 162 for pneumonia occurred. The overall post-discharge 30 day mortality was 8.7% for heart failure, 7.3% for acute myocardial infarction, and 8.4% for pneumonia. Risk adjusted mortality increased annually by 0.05% (95% confidence interval 0.02% to 0.08%) for heart failure, decreased by 0.06% (−0.09% to −0.04%) for acute myocardial infarction, and did not significantly change for pneumonia. Specifically, mortality increased for patients with heart failure who did not utilize any post-discharge acute care, increasing at a rate of 0.08% (0.05% to 0.12%) per year, exceeding the overall absolute annual increase in post-discharge mortality in heart failure, without an increase in mortality in observation units or the emergency department. Concurrent with a reduction in 30 day readmission rates, stays for observation and visits to the emergency department increased across all three conditions during and beyond the 30 day post-discharge period. Overall 30 day post-acute care utilization did not change significantly. Conclusions The only condition with increasing mortality through the study period was heart failure; the increase preceded the policy and was not present among patients who received emergency department or observation unit care without admission to hospital. During this period, the overall acute care utilization in the 30 days after discharge significantly decreased for heart failure and pneumonia, but not for acute myocardial infarction.
Tumor Endothelial Markers (TEMS) as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer (NSCLC)
Authors: A. Pircher, G. Untergasser, I.M. Heidegger, J. Kern, E. Gunsilius, M. Fiegl, W. Hilbe
Journal: Annals of Oncology (2012)
Abstract 17962: Novel Duplex Steel Stent Enables Nanoparticle Mediated Cell Capture and Demonstrates Endothelialization at Three Days
Authors: Brandon J Tefft, Susheil Uthamaraj, James J Harburn, Martin Klabusay, Ota Hlinomaz, David R Holmes, Robert D Simari, Dan Dragomir-Daescu, Gurpreet S Sandhu
Journal: Circulation (2013)

Introduction: The feasibility of using super-paramagnetic iron oxide nanoparticle (SPION) labeled endothelial outgrowth cells (EOC) to coat the surface of prototype magnetic stents has been shown p...
The experience in the management of 15 patients with chronic myeloid leukemia (CML) in a community clinic in Puerto Rico.
Authors: Justiniano Castro
Journal: Journal of Clinical Oncology (2013)

e18015 Background: CML is a malignant clonal disorder of the hematopoietic stem cells that results in an increased myeloid cells but also erythroid and platelets in the peripheral blood and marked myeloid hyperplasia in the bone marrow. The management of this condition in a rural community clinic is a challenge due to the complexity in the routine monitor of these patients with molecular studies. In addition, data from Hispanic population treated with imatinib in USA is limited. Methods: A total of 15 patient with CML followed in a private clinic form June 2001 to January 2012 were included in the analysis for the study. Results: The patients included 10 males and 5 females. Median age was 51 years. All patients received imatinib 400mg. There were 4 patients with initial WBC &gt; 50,000/mm3. All patients were in chronic phase with less 1% of blasts, except for one that had 7%. Twelve patients had a low Harford score, 2 with moderate and 1 high risk. Conclusions: Our data suggest that imatinib is highly effective in this population of patients. The CCR at 6 months was 80% and the MMR at 12 months was 80% compared with the data from the IRIS (CCR at 6 months, 74.7%) and DASISON (MMR at 12 months, 28%) trials. This group of patients demonstrates high CHR, CCR and MMR in comparison of what is reported in the literature. The study also present a group of Hispanic patients were the information about imatinib response is limited. The possibly that certain ethnic group has a different pattern of response as compared with Caucasian is intriguing. Lastly, it is evident that adequate care could be offer event in rural community clinics. [Table: see text]
Decreased sphingolipid synthesis in children with 17q21 asthma–risk genotypes
Authors: Jennie G. Ono, Benjamin I. Kim, Yize Zhao, Paul J. Christos, Yohannes Tesfaigzi, Tilla S. Worgall, Stefan Worgall
Journal: Journal of Clinical Investigation (2020)

Risk for childhood asthma is conferred by alleles within the 17q21 locus affecting ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) expression. ORMDL3 inhibits sphingolipid de novo synthesis. Although the effects of 17q21 genotypes on sphingolipid synthesis in human asthma remain unclear, both decreased sphingolipid synthesis and ORMDL3 overexpression are linked to airway hyperreactivity. To characterize the relationship of genetic asthma susceptibility with sphingolipid synthesis, we analyzed asthma-associated 17q21 genotypes (rs7216389, rs8076131, rs4065275, rs12603332, and rs8067378) in both children with asthma and those without asthma, quantified plasma and whole-blood sphingolipids, and assessed sphingolipid de novo synthesis in peripheral blood cells by measuring the incorporation of stable isotope-labeled serine (substrate) into sphinganine and sphinganine-1-phosphate. Whole-blood dihydroceramides and ceramides were decreased in subjects with the 17q21 asthma-risk alleles rs7216389 and rs8076131. Children with nonallergic asthma had lower dihydroceramides, ceramides, and sphingomyelins than did controls. Children with allergic asthma had higher dihydroceramides, ceramides, and sphingomyelins compared with children with nonallergic asthma. Additionally, de novo sphingolipid synthesis was lower in children with asthma compared with controls. These findings connect genetic 17q21 variations that are associated with asthma risk and higher ORMDL3 expression to lower sphingolipid synthesis in humans. Altered sphingolipid synthesis may therefore be a critical factor in asthma pathogenesis and may guide the development of future therapeutics.
Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with Bev-Based Therapy: Overall Survival Subgroup Findings from ML18147
Authors: J.M. Vieitez de Prado, C. Borg, D. Arnold, R. Greil, E.J.D. Van Cutsem, R. von Moos, J. Bennouna, I. Reyes-Rivera, B. Bendahmane, S. Kubicka
Journal: Annals of Oncology (2012)
Chlorhexidine for the Prevention of Bloodstream Infection (BSI) Associated with Permanently Implantable Venous Ports (Port-A) In Solid Cancer Patients: A Prospective Cohort Study
Authors: H. Kao, I. Chen, S. Chang, M. Hong, S. Chien, F. Hu, C. Hsu, K. Yeh
Journal: Annals of Oncology (2012)
Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Dialysis
Authors: Toshiki Kuno, Hisato Takagi, Tomo Ando, Takehiro Sugiyama, Satoshi Miyashita, Nelson Valentin, Yuichi J. Shimada, Masaki Kodaira, Yohei Numasawa, Alexandros Briasoulis, Alfred Burger, Sripal Bangalore
Journal: Journal of the American College of Cardiology (2020)
A Retrospective Analysis of Cervical Cancer Patients Treated with Carboplatin and Paclitaxel in First Palliative Line at Brazilian National Cancer Institute (INCA)
Authors: A.H. Ingles Garces, P. Mora, F. Alves, A. Mangia, C. Calazan, A. Rodrigues, A. Melo
Journal: Annals of Oncology (2012)
Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients: A Prospective Randomized Controlled Trial
Authors: Kwang Jin Ko, Won Jin Cho, Young-Suk Lee, Joongwon Choi, Hye Jin Byun, Kyu-Sung Lee
Journal: European Urology (2020)